Skip to main content

MEDICURE INC

corporate_fare Company Profile

MEDICURE INC

MCUJF·OTC·Life Sciences·CIK 0001133519

Medicure Inc. is a pharmaceutical company that acquired the U.S. rights to its first commercial product, AGGRASTAT Injection (tirofiban hydrochloride), in August 2006 for US$19.0 million. This product is sold in the United States and its territories, including Puerto Rico, the Virgin Islands, and Guam. In September 2007, the company secured US$25 million through a debt financing agreement with Birmingham Associates Ltd., an affiliate of Elliott Associates, L.P., by monetizing a percentage of its current and potential future commercial revenues. This debt was settled in July 2011, which included a royalty agreement payable to Birmingham based on future commercial AGGRASTAT sales until 2023. The royalty structure is four percent on the first $2.0 million of quarterly AGGRASTAT sales, six percent on sales between $2.0 million and $4.0 million, and eight percent on sales exceeding $4.0 million, payable within 60 days of the quarter's end. In February 2008, the company's pivotal Phase III MEND-CABG II clinical trials with MC-1 did not meet the primary endpoint, leading to a restructuring plan in March 2008 that reduced its workforce by approximately 50 employees and full-time consultants to conserve capital. On July 18, 2011, Medicure Inc. borrowed $5,000,000 from the Government of Manitoba under the Manitoba Industrial Opportunities Program to help settle its debt to Birmingham. The company's registered and head office is located at 2-1250 Waverley Street, Winnipeg, Manitoba, Canada, R3T 6C6.

MEDICURE INC (OTC:MCUJF) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 7 items for MCUJF at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-28, rated 7/10. Across its 7 most recent items scored 7 or higher, the top rating is 9/10, with 4 rated 8 or above. Recent SEC coverage for MCUJF spans 6-K, 20-F.

Recent high-impact activity:

  • Medicure Completes Enrollment in Pivotal Phase 3 Trial for Ultra-Rare PNPO Deficiency
  • Medicure Reports Widened Q2 Loss and Significant Cash Burn Despite Revenue Growth
  • Medicure Reports Q1 Revenue Growth and Improved EBITDA, but Significant Cash Burn
  • MEDICURE Reports Q1 Revenue Growth, But Significant Cash Burn Raises Liquidity Concerns
  • Medicure Reports Strong Q1 Revenue Growth, Reduced Net Loss, and Improved EBITDA

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
CA$28.86M CAD
Net Income
-CA$7.1M CAD
Diluted EPS
-CA$0.68 CAD
Op. Cash Flow
-CA$560K CAD
Gross Profit
CA$11.75M CAD
Cash & Equivalents
CA$3.83M CAD
Debt / Equity
0.00×
Net Margin
-24.6%
Source: 20-F · filed 2026-04-23 · accession 0001654954-26-003871

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 16,610 shares in MCUJF as of the October 30, 2026 settlement, a 396.1% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 42.8% of MCUJF volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)16,610 shares as of October 30, 2026
Change vs prior period▲ 396.1%
Days to cover1.00 at avg daily volume of 29,975
Daily short volume (FINRA facilities)42.8% of 28,215 shares on November 20, 2026
5-day average short volume70.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Insider Transactions

MCUJF files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with M →
$2.7 +5.52% today
52-week range · as of 2026-08-19 $0.4359 – $2.7
Market cap
$28.14M
Volume
28.2K (1.3× avg)
3-mo avg 21K
Live data · 2026-11-21 11:57 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed MCUJF - Latest Insights

MCUJF
Sep 28, 2026, 6:00 PM EDT
Source: ACCESS Newswire
Importance Score:
7
Price at Filing: $2.00
Real-time Price: $2.70 info
Change: +$0.696 (+35%) info
Market Cap: $28.136M info
MCUJF
Aug 19, 2026, 4:35 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.915
Real-time Price: $2.70 info
Change: +$1.78 (+195%) info
Market Cap: $28.136M info
MCUJF
May 21, 2026, 5:18 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.8039
Real-time Price: $2.70 info
Change: +$1.89 (+235%) info
Market Cap: $28.136M info
MCUJF
May 21, 2026, 5:18 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.8039
Real-time Price: $2.70 info
Change: +$1.89 (+235%) info
Market Cap: $28.136M info
MCUJF
May 21, 2026, 5:00 PM EDT
Source: ACCESS Newswire
Importance Score:
8
Price at Filing: $0.8039
Real-time Price: $2.70 info
Change: +$1.89 (+235%) info
Market Cap: $28.136M info
MCUJF
Apr 23, 2026, 6:26 PM EDT
Filing Type: 20-F
Importance Score:
9
Price at Filing: $0.9633
Real-time Price: $2.70 info
Change: +$1.73 (+180%) info
Market Cap: $28.136M info
MCUJF
Apr 17, 2026, 7:35 PM EDT
Source: Access Newswire
Importance Score:
7
Price at Filing: $0.9633
Real-time Price: $2.70 info
Change: +$1.73 (+180%) info
Market Cap: $28.136M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets